These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 9299439)

  • 1. Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains.
    Feil R; Wagner J; Metzger D; Chambon P
    Biochem Biophys Res Commun; 1997 Aug; 237(3):752-7. PubMed ID: 9299439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: comparison of the recombinase activity of the tamoxifen-inducible Cre-ER(T) and Cre-ER(T2) recombinases.
    Indra AK; Warot X; Brocard J; Bornert JM; Xiao JH; Chambon P; Metzger D
    Nucleic Acids Res; 1999 Nov; 27(22):4324-7. PubMed ID: 10536138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conditional site-specific recombination in mammalian cells using a ligand-dependent chimeric Cre recombinase.
    Metzger D; Clifford J; Chiba H; Chambon P
    Proc Natl Acad Sci U S A; 1995 Jul; 92(15):6991-5. PubMed ID: 7624356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.
    MacGregor Schafer J; Liu H; Bentrem DJ; Zapf JW; Jordan VC
    Cancer Res; 2000 Sep; 60(18):5097-105. PubMed ID: 11016635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse.
    Hayashi S; McMahon AP
    Dev Biol; 2002 Apr; 244(2):305-18. PubMed ID: 11944939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A triple mutant of the Drosophila ERR confers ligand-induced suppression of activity.
    Ostberg T; Jacobsson M; Attersand A; Mata de Urquiza A; Jendeberg L
    Biochemistry; 2003 Jun; 42(21):6427-35. PubMed ID: 12767224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inducible site-directed recombination in mouse embryonic stem cells.
    Zhang Y; Riesterer C; Ayrall AM; Sablitzky F; Littlewood TD; Reth M
    Nucleic Acids Res; 1996 Feb; 24(4):543-8. PubMed ID: 8604292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Yeast two-hybrid system demonstrates that estrogen receptor dimerization is ligand-dependent in vivo.
    Wang H; Peters GA; Zeng X; Tang M; Ip W; Khan SA
    J Biol Chem; 1995 Oct; 270(40):23322-9. PubMed ID: 7559488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Site- and time-specific gene targeting in the mouse.
    Metzger D; Chambon P
    Methods; 2001 May; 24(1):71-80. PubMed ID: 11327805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of Cre recombinase toxicity in proliferating Drosophila cells by estrogen-dependent activity regulation.
    Heidmann D; Lehner CF
    Dev Genes Evol; 2001 Sep; 211(8-9):458-65. PubMed ID: 11685583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists.
    Mahfoudi A; Roulet E; Dauvois S; Parker MG; Wahli W
    Proc Natl Acad Sci U S A; 1995 May; 92(10):4206-10. PubMed ID: 7753783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FLP recombinase/estrogen receptor fusion proteins require the receptor D domain for responsiveness to antagonists, but not agonists.
    Nichols M; Rientjes JM; Logie C; Stewart AF
    Mol Endocrinol; 1997 Jun; 11(7):950-61. PubMed ID: 9178754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inducible site-specific recombination in the brain.
    Kellendonk C; Tronche F; Casanova E; Anlag K; Opherk C; Schütz G
    J Mol Biol; 1999 Jan; 285(1):175-82. PubMed ID: 9878397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ligand-activated site-specific recombination in mice.
    Feil R; Brocard J; Mascrez B; LeMeur M; Metzger D; Chambon P
    Proc Natl Acad Sci U S A; 1996 Oct; 93(20):10887-90. PubMed ID: 8855277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins.
    Littlewood TD; Hancock DC; Danielian PS; Parker MG; Evan GI
    Nucleic Acids Res; 1995 May; 23(10):1686-90. PubMed ID: 7784172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of bacterially expressed rat estrogen receptor beta ligand binding domain by mass spectrometry: structural comparison with estrogen receptor alpha.
    Witkowska HE; Carlquist M; Engström O; Carlsson B; Bonn T; Gustafsson JA; Shackleton CH
    Steroids; 1997; 62(8-9):621-31. PubMed ID: 9292936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The inhibitory activity of a transdominant c-jun mutant fused to the ligand binding domain of the estrogen receptor.
    Kim S; Brown PH; Birrer MJ
    Oncogene; 1996 Mar; 12(5):1043-53. PubMed ID: 8649795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the tamoxifen regulated chimeric Cre recombinases MerCreMer and CreMer.
    Verrou C; Zhang Y; Zürn C; Schamel WW; Reth M
    Biol Chem; 1999 Dec; 380(12):1435-8. PubMed ID: 10661871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A tamoxifen-inducible chimeric Cre recombinase specifically effective in the fetal and adult mouse liver.
    Tannour-Louet M; Porteu A; Vaulont S; Kahn A; Vasseur-Cognet M
    Hepatology; 2002 May; 35(5):1072-81. PubMed ID: 11981757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor.
    Levenson AS; Jordan VC
    Cancer Res; 1998 May; 58(9):1872-5. PubMed ID: 9581827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.